Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease save search
Zhongchao Inc. Launched New Line of Business Focusing on Tumor and Rare Disease Patient Management
Published: 2021-05-28 (Crawled : 11:00) - prnewswire.com
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
|
| O: 5.88%
H: 1.01%
C: -11.11%
disease rare
Zhongchao Inc. Announces its MDMOOC Platform Launched Disease Prevention and Distribution Quality Management Course
Published: 2022-06-13 (Crawled : 11:00) - prnewswire.com
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
|
| O: -9.73%
H: 12.93%
C: -0.93%
management disease distribution platform
Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management
Published: 2022-09-01 (Crawled : 12:00) - prnewswire.com
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
|
| O: 0.85%
H: 0.85%
C: -2.12%
management disease extension
Zhongchao Inc. Introduces PRO-Based Disease Management Model for Lung Cancer Patients
Published: 2023-09-25 (Crawled : 12:00) - prnewswire.com
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
|
| O: 1.77%
H: 0.0%
C: -1.74%
lung management disease cancer
Zhongchao Inc. Announces Serving over 10,000 Breast Cancer Patients with Its Comprehensive Disease Management
Published: 2023-08-24 (Crawled : 12:00) - prnewswire.com
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
|
| O: 1.75%
H: 0.0%
C: -2.59%
management disease breast cancer
Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases
Published: 2021-04-22 (Crawled : 12:00) - biospace.com/
APM | $5.9 9.87% 8.98% 37K
|
Health Technology
|
| O: 4.45%
H: 5.43%
C: -1.94%
disease potential license
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics
Published: 2022-09-15 (Crawled : 14:00) - biospace.com/
APM | $5.9 9.87% 8.98% 37K
|
Health Technology
|
| O: 2.07%
H: 6.08%
C: 3.38%
disease diagnostics molecular group
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted
Published: 2022-04-25 (Crawled : 17:00) - biospace.com/
APM | $5.9 9.87% 8.98% 37K
|
Health Technology
|
| O: -3.52%
H: 11.68%
C: -6.57%
patent disease technology granted grant
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
Published: 2023-07-11 (Crawled : 13:00) - biospace.com/
MAIA | $2.15 9.69% 0.0% 100K
|
|
| O: 0.0%
H: 4.52%
C: -3.62%
thio-101 lung disease control cancer cell trial
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
Published: 2023-10-24 (Crawled : 13:30) - biospace.com/
MAIA | $2.15 9.69% 0.0% 100K
|
|
| O: 19.49%
H: 4.72%
C: -12.88%
thio-101 lung disease control positive cancer cell ongoing trial
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
Published: 2022-06-21 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 5.29%
H: 0.0%
C: 0.0%
lancet publication chikungunya disease phase 2
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Published: 2022-07-06 (Crawled : 12:20) - biospace.com/
KZIA | $0.379 9.47% 8.65% 300K
|
Health Technology
|
| O: 13.91%
H: 0.0%
C: -13.47%
fda rare designation awards disease paxalisib cancer train
BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
Published: 2021-01-05 (Crawled : 12:03) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: -0.48%
H: 1.35%
C: -8.19%
disease alzheimer dementia phase 1b alzheimer’s alzheimer's disease alzheimer's phase 2b
BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2021-12-15 (Crawled : 12:30) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: -3.82%
H: 8.09%
C: 7.79%
bxcl501 alzheimer treatment therapeutics disease cel phase 3 alzheimer’s alzheimer's disease alzheimer's
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2022-05-03 (Crawled : 12:20) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 4.1%
H: 1.65%
C: 1.01%
treatment disease trial therapeutics alzheimer’s phase 3 alzheimer's
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2022-12-19 (Crawled : 12:20) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 1.0%
H: 0.67%
C: -1.23%
treatment disease trial therapeutics alzheimer’s
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
Published: 2024-02-05 (Crawled : 12:00) - globenewswire.com
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 9.48%
H: 15.37%
C: 10.75%
patent disease alzheimer’s application therapeutics
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
Published: 2022-02-15 (Crawled : 14:00) - biospace.com/
PSNL | $1.31 8.26% 7.63% 280K
|
Health Technology
|
| O: 2.42%
H: 1.84%
C: -0.96%
genomic announces collaboration research disease test collaboration cancer biomarkers
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
Published: 2022-07-12 (Crawled : 22:00) - biospace.com/
PSNL | $1.31 8.26% 7.63% 280K
|
Health Technology
|
| O: 0.53%
H: 3.17%
C: 2.9%
expansion patent disease molecular
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Published: 2023-03-07 (Crawled : 15:00) - biospace.com/
PSNL | $1.31 8.26% 7.63% 280K
|
Health Technology
|
| O: 1.03%
H: 7.76%
C: 3.07%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.9%
H: 0.28%
C: -1.3%
research disease molecular
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.